Rani Therapeutics (NASDAQ:RANI - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $11.00 price target on the stock.
Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Rani Therapeutics in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.33.
Get Our Latest Research Report on RANI
Rani Therapeutics Stock Performance
NASDAQ RANI opened at $1.08 on Friday. The stock's fifty day moving average is $1.29 and its two-hundred day moving average is $1.30. The firm has a market capitalization of $131.23 million, a P/E ratio of -1.37 and a beta of 0.39. Rani Therapeutics has a fifty-two week low of $0.39 and a fifty-two week high of $3.87.
Rani Therapeutics (NASDAQ:RANI - Get Free Report) last issued its earnings results on Thursday, March 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $1.46 million during the quarter, compared to the consensus estimate of $5.00 million. As a group, sell-side analysts forecast that Rani Therapeutics will post -1.01 EPS for the current year.
Hedge Funds Weigh In On Rani Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in Rani Therapeutics during the fourth quarter worth about $11,475,000. AWM Investment Company Inc. acquired a new stake in shares of Rani Therapeutics during the fourth quarter worth about $8,775,000. SymBiosis Capital Partners LLC purchased a new position in shares of Rani Therapeutics in the fourth quarter valued at approximately $8,505,000. Armistice Capital LLC acquired a new position in shares of Rani Therapeutics in the second quarter valued at approximately $1,619,000. Finally, Siren L.L.C. acquired a new position in shares of Rani Therapeutics in the fourth quarter valued at approximately $2,700,000. 30.19% of the stock is currently owned by hedge funds and other institutional investors.
About Rani Therapeutics
(
Get Free Report)
Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company's proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.
Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rani Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.
While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
